BIO-TECHNE (NASDAQ:TECH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Saturday. The firm currently has a $148.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 10.79% from the company’s current price.
According to Zacks, “Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota. “
Other analysts have also recently issued reports about the company. Deutsche Bank set a $145.00 price target on BIO-TECHNE and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Citigroup reaffirmed a “buy” rating and issued a $115.00 price objective (down from $125.00) on shares of BIO-TECHNE in a research report on Tuesday, October 24th. Craig Hallum reaffirmed a “buy” rating and issued a $160.00 price objective (up from $140.00) on shares of BIO-TECHNE in a research report on Wednesday. Robert W. Baird reaffirmed a “buy” rating and issued a $154.00 price objective on shares of BIO-TECHNE in a research report on Thursday, January 18th. Finally, BidaskClub raised BIO-TECHNE from a “hold” rating to a “buy” rating in a research report on Wednesday, January 10th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $145.00.
BIO-TECHNE (NASDAQ:TECH) last issued its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.10. BIO-TECHNE had a return on equity of 14.39% and a net margin of 19.17%. The firm had revenue of $154.15 million for the quarter, compared to analysts’ expectations of $145.93 million. During the same period in the previous year, the firm posted $0.81 EPS. The business’s revenue for the quarter was up 16.9% compared to the same quarter last year. sell-side analysts forecast that BIO-TECHNE will post 3.93 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC lifted its position in BIO-TECHNE by 28.8% in the 4th quarter. Citadel Advisors LLC now owns 416,736 shares of the biotechnology company’s stock valued at $53,988,000 after acquiring an additional 93,175 shares in the last quarter. American International Group Inc. lifted its position in BIO-TECHNE by 1.6% in the 4th quarter. American International Group Inc. now owns 77,603 shares of the biotechnology company’s stock valued at $10,053,000 after acquiring an additional 1,228 shares in the last quarter. Virtus Fund Advisers LLC lifted its position in BIO-TECHNE by 71.0% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,324 shares of the biotechnology company’s stock valued at $301,000 after acquiring an additional 965 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of BIO-TECHNE by 27.6% during the 4th quarter. Arizona State Retirement System now owns 26,966 shares of the biotechnology company’s stock valued at $3,493,000 after buying an additional 5,833 shares during the period. Finally, Eagle Asset Management Inc. lifted its holdings in shares of BIO-TECHNE by 1.5% during the 4th quarter. Eagle Asset Management Inc. now owns 56,837 shares of the biotechnology company’s stock valued at $7,444,000 after buying an additional 842 shares during the period. 96.89% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/02/10/bio-techne-tech-lifted-to-buy-at-zacks-investment-research.html.
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.